Apitoria Pharma Private Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is EMPAGLIFLOZIN, with a corresponding US DMF Number 32454.
Remarkably, this DMF maintains an Active status since its submission on January 24, 2018, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of March 27, 2018, and payment made on January 23, 2018, indicating their dedication to facilitating drug approvals, Categorized as Type II